Detailed price information for Amicus Therapeutics (FOLD-Q) from The Globe and Mail including charting and trades.

Amicus Therapeutics (FOLD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Learn more about whether ADMA Biologics, Inc. or Amicus Therapeutics, Inc. is a better investment based on AAII's A+ Investor ...

Assetmark Inc. Scales Down Stake in Amicus Therapeutics Amid Strategic Portfolio Rebalancing | S&P 500 Futures Tracker ...

Highlights,XTX Topco Ltd significantly increased its position in Amicus Therapeutics during the first quarter,Shares of ...

As you might know, Amicus Therapeutics, Inc. ( NASDAQ:FOLD ) just kicked off its latest second-quarter results ...

Amicus Therapeutics (($FOLD)) has held its Q2 earnings call. Read on for the main highlights of the call. Amicus Therapeutics’ recent earnings ...

Amicus Therapeutics is building momentum with strong sales growth from GALAFOLD and POMBILITI/OPFOLDA. Click here to find out ...

Discover Amicus Therapeutics' Q2 2025 growth insights, double-digit revenue gains, pipeline milestones, and confidence in $1B sales targets for ...

Amicus Therapeutics, Inc. (NASDAQ: FOLD) is one of the best strong buy stocks to buy under $10. In a report released on July ...

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -50.00% and +4.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Second Quarter 2025 Financial Highlights: Total revenues for the second quarter 2025 were $154.7 million, reflecting strong ...